Plans to alter routine childhood immunisation schedule announced

From 1st July 2016, infants will no longer receive vaccination against meningococcal serogroup C (MenC), currently given at three months of age.

The dose of combined Hib/Men C offered at 12 months of age will provide good protection to toddlers and younger children. | iStock
The dose of combined Hib/Men C offered at 12 months of age will provide good protection to toddlers and younger children. | iStock

The change to the routine immunisation schedule is based on a recommendation from the Joint Committee on Vaccination and Immunisation (JCVI) in light of the success of the MenC programme in limiting cases of invasive MenC disease. It is believed that ongoing vaccination of adolescents will sustain the high level of herd protection. 

Further information
View MenC vaccine drug record
Letter from PHE

In addition, the new MenB vaccination programme with Bexsero may provide some degree of protection against invasive MenC disease.

Children will continue to be offered the Hib/MenC vaccine (Menitorix) at 12 months of age and the MenACWY conjugate vaccine (Menveo/Nimenrix) at around 14 years of age. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more